TSE:4534Pharmaceuticals
Mochida Pharmaceutical (TSE:4534) Stock Faces Margin Squeeze Despite Revenue Growth
Mochida Pharmaceutical stock has been drifting lower in recent months, yet the latest quarter puts the focus firmly on profitability rather than the share price slide. The headline is margin pressure. Quarterly net income and earnings per share sit well below the stronger results seen in late 2026, even as the trailing 12 month net margin of 6.8% looks better than a year ago.
For you as an investor, this earnings print is about whether that improving trailing margin can offset the shorter...